Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00157911
Status:
COMPLETED
Last Update Posted:
2022-02-16
First Post:
2005-09-07
Brief Title:
A Study to Evaluate Ezetimibe in Korean Patients With Primary Hypercholesterolemia 0653-042
Sponsor:
Organon and Co
Organization:
Organon and Co
Study Overview
Official Title:
A Double-Blind Randomized Multicenter Active-Comparative 12-Week Study to Assess the Efficacy and Safety of the Drug in Conjunction With Another Drug in Korean Patients With Primary Hypercholesterolemia
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients undergo 4-week placebo lead-in and diet period and 12-week treatment period Clinical efficacy and safety is evaluated at weeks 4 8 and 12 This study takes approximately 18 weeks for an individual patient to complete including post-visit at week 14
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_065 | None | None | None |
| MK0653-042 | None | None | None |